Cystic Fibrosis Transmembrane Conductance Regulator
"Cystic Fibrosis Transmembrane Conductance Regulator" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A chloride channel that regulates secretion in many exocrine tissues. Abnormalities in the CFTR gene have been shown to cause cystic fibrosis. (Hum Genet 1994;93(4):364-8)
Descriptor ID |
D019005
|
MeSH Number(s) |
D12.776.157.530.100.304.500 D12.776.157.530.400.175.125 D12.776.157.530.450.074.500.500.500.500 D12.776.543.550.450.175.125 D12.776.543.585.100.304.500 D12.776.543.585.400.175.125 D12.776.543.585.450.074.500.500.500.500
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Cystic Fibrosis Transmembrane Conductance Regulator".
Below are MeSH descriptors whose meaning is more specific than "Cystic Fibrosis Transmembrane Conductance Regulator".
This graph shows the total number of publications written about "Cystic Fibrosis Transmembrane Conductance Regulator" by people in this website by year, and whether "Cystic Fibrosis Transmembrane Conductance Regulator" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2019 | 0 | 1 | 1 |
2021 | 0 | 1 | 1 |
2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cystic Fibrosis Transmembrane Conductance Regulator" by people in Profiles.
-
Elexacaftor/tezacaftor/ivacaftor treatment reduces airway inflammation in cystic fibrosis. Pediatr Pulmonol. 2023 05; 58(5):1592-1594.
-
A dyadic approach to the delineation of diagnostic entities in clinical genomics. Am J Hum Genet. 2021 01 07; 108(1):8-15.
-
Effect of CFTR modulator therapy on cystic fibrosis-related diabetes. J Diabetes Complications. 2021 06; 35(6):107845.
-
Novel cystamine-core dendrimer-formulation rescues ?F508-CFTR and inhibits Pseudomonas aeruginosa infection by augmenting autophagy. Expert Opin Drug Deliv. 2019 02; 16(2):177-186.
-
Sustained Glycemic Control With Ivacaftor in Cystic Fibrosis-Related Diabetes. J Investig Med High Impact Case Rep. 2019 Jan-Dec; 7:2324709619842898.
-
Autophagy augmentation alleviates cigarette smoke-induced CFTR-dysfunction, ceramide-accumulation and COPD-emphysema pathogenesis. Free Radic Biol Med. 2019 02 01; 131:81-97.
-
Inhibition of histone-deacetylase activity rescues inflammatory cystic fibrosis lung disease by modulating innate and adaptive immune responses. Respir Res. 2018 01 04; 19(1):2.
-
Cigarette Smoke Exposure Inhibits Bacterial Killing via TFEB-Mediated Autophagy Impairment and Resulting Phagocytosis Defect. Mediators Inflamm. 2017; 2017:3028082.
-
Dendrimer-based selective autophagy-induction rescues ?F508-CFTR and inhibits Pseudomonas aeruginosa infection in cystic fibrosis. PLoS One. 2017; 12(9):e0184793.
-
Augmentation of S-Nitrosoglutathione Controls Cigarette Smoke-Induced Inflammatory-Oxidative Stress and Chronic Obstructive Pulmonary Disease-Emphysema Pathogenesis by Restoring Cystic Fibrosis Transmembrane Conductance Regulator Function. Antioxid Redox Signal. 2017 Sep 01; 27(7):433-451.